60 Degrees Reports Negative Babesia PCR Results In Completed Expanded Access Patients; Stock Down
60 Degrees Pharmaceuticals (SXTP) reported negative PCR results in 5 patients from its expanded access study of tafenoquine for babesiosis, with 4 also testing negative on a sensitive NAT test. All patients showed clinical improvement. The stock is down 29% to $0.60. The company expects to unblind a separate study in January 2027. Tafenoquine is not FDA-approved for babesiosis.
How this was made
The 30-second read
Why it matters
The negative PCR results and mixed NAT findings raise questions about the drug's efficacy, likely pressuring the stock further.
Market read
The trial update is the first public disclosure of efficacy data, making it material for traders focused on small‑cap biotech stocks.
What to watch
The study size is very small (seven patients) and results are preliminary; future larger trials could change the outlook.
Background
60 Degrees Pharmaceuticals is developing tafenoquine‑based regimens for relapsing babesiosis, a tick‑borne disease with limited treatment options.
Ticker impact
60 Degrees reported negative PCR results and mixed NAT outcomes for its expanded access babesiosis study, indicating limited efficacy.
downward pressure as investors reassess the drug's prospects
The study showed all five completed patients had negative PCR, but one remained NAT‑positive, and the stock is already down 29% on the news.
Market effects
May dampen sentiment toward emerging infectious disease therapeutics and affect peer biotech valuations.
Limited to U.S. biotech investors; no broader regional effect.
Low global impact; primarily relevant to niche biotech and infectious‑disease investors.
Counterpoint
If the drug shows safety and a path to FDA approval, some investors may view the data as a stepping stone rather than a failure.
Key entities
- Company60 Degrees Pharmaceuticals
Biotech firm developing tafenoquine for babesiosis.
- RegulatorU.S. FDA
Potential reviewer of future trial data and sNDA submission.
